A 48-year-old woman from Mumbai with Child-Pugh class B cirrhosis presents with acute variceal bleeding from esophageal varices. After successful endoscopic variceal ligation, she is stabilized. Imaging shows a patent portal vein with flow toward the liver, and the varices are confirmed to originate from portal hypertension. She is now euvolemic and hemodynamically stable. What is the most appropriate next step to prevent variceal rebleeding?

Explanation

## Clinical Context The patient has cirrhotic portal hypertension with variceal bleeding controlled by endoscopic therapy. The goal now is **secondary prophylaxis** (prevention of rebleeding). ## Portal Hypertension Pathophysiology **Key Point:** Portal hypertension in cirrhosis results from increased intrahepatic resistance and splanchnic vasodilation. The **portal vein** (formed by confluence of superior and inferior mesenteric veins and splenic vein) normally carries blood from the GI tract to the liver. When portal pressure exceeds 12 mmHg (normal ~5 mmHg), esophageal varices form. **Mnemonic:** **Portal Vein Tributaries** = **SMV + IMV + SV** (Superior Mesenteric Vein + Inferior Mesenteric Vein + Splenic Vein). ## Secondary Prophylaxis Algorithm ```mermaid flowchart TD A[Variceal bleed controlled<br/>by endoscopy]:::outcome --> B{Hemodynamically stable?}:::decision B -->|Yes| C[Beta-blocker therapy]:::action C --> D[Target HR reduction<br/>20-25% or HR 55 bpm]:::action D --> E[Repeat EGD in 2 weeks<br/>for ligation]:::action E --> F[Continue beta-blocker<br/>indefinitely]:::action B -->|No: Rebleeding,<br/>hemodynamic instability| G[TIPS]:::urgent ``` ## Beta-Blocker Therapy: Evidence & Mechanism - **Mechanism:** Non-selective beta-blockers (propranolol, nadolol, carvedilol) reduce portal pressure by: 1. Decreasing cardiac output (β₁ blockade) 2. Reducing splanchnic blood flow (β₂ blockade of splanchnic vasodilation) 3. Net effect: reduction in portal pressure gradient - **Target:** Heart rate reduction of **20–25%** from baseline OR absolute heart rate of **55 bpm**, whichever is lower [cite:AASLD Portal Hypertension Guidelines 2020]. - **Efficacy:** Reduces rebleeding risk from ~60% (without prophylaxis) to ~30–40% over 2 years. **High-Yield:** Beta-blockers are the **first-line pharmacologic agent** for secondary prophylaxis of variceal bleeding in cirrhosis. ## Endoscopic Therapy - **Variceal ligation (EVL):** Mechanical obliteration; superior to sclerotherapy (less rebleeding, fewer complications). - **Timing of repeat EGD:** 2–4 weeks after initial ligation to assess for variceal eradication and apply additional ligation if needed. - **EVL alone vs. EVL + beta-blocker:** Combined therapy (EVL + beta-blocker) is superior to EVL alone for secondary prophylaxis. **Clinical Pearl:** Beta-blockers should be continued **indefinitely** in cirrhotic patients with a history of variceal bleeding, even after variceal eradication, because portal hypertension persists.